Quel est le prix actuel de Bio Protocol ?
Le prix actuel de Bio Protocol est 0,02371 € avec un changement de 1,07 % au cours des dernières 24 heures.
Bio Protocol is a funding and liquidity layer for decentralized science, built so that communities of patients, researchers and crypto users can collectively fund biotech projects and share in the intellectual property they produce. The project describes itself as "a new financial layer for funding and developing early-stage biotech" whose mission is to "reshape how biotech breakthroughs are born by enabling global communities of patients, researchers and crypto users to create user-owned research networks." In practice it curates and launches BioDAOs, community-owned research organizations such as VitaDAO and CryoDAO, and then provides them with launch infrastructure, liquidity and governance tooling. BIO is the protocol's native utility and governance token and the pairing asset for the project tokens it launches.
Official resources:
Bio Protocol's documentation does not name its core team, which is worth stating plainly. The bio.xyz site does list contributors by function, including Paul Kohlhaas on tokenomics, Clemens Ortlepp on product, Elliott Brunet on tech, Jose Pinto as legal counsel, and Ritvik Singh and Johannes Weniger on AI. Kohlhaas is widely reported as the founder of both Molecule and Bio Protocol, with Tyler Golato reported as a co-founder of Molecule, VitaDAO and Bio; those attributions come from interviews and press coverage rather than protocol documentation.
The lineage runs through Molecule AG, which pioneered the IP tokenization framework Bio uses, and through VitaDAO, the longevity research DAO launched in 2021 that became the template for later BioDAOs. Bio Protocol itself emerged as the shared layer beneath those communities. BIO was distributed through Binance Launchpool, with farming running from December 24, 2024 to January 2, 2025 and the token listed on January 3, 2025. Backers named on the site include Binance Labs, YZi Labs, 1kx, Northpond Ventures and 50y, with Pfizer Ventures cited as a participant in a VitaDAO round.
Bio operates as a launchpad, a liquidity manager and a governance layer for scientific projects.
Projects enter the ecosystem through one of two tracks. "Community Launches are the permissionless track. Any team that meets baseline criteria can launch with lighter Bio involvement," while "Curated Launches prioritize selectivity and deeper support." Sales are run as transparent fixed-price offerings, and "successfully raised funds can automatically be injected into onchain liquidity pools," so a project leaves its raise with a functioning market rather than an illiquid token.
BIO holders participate by staking. "Stake BIO to receive veBIO, which provides voting power on protocol upgrades and meta-governance over assets in the treasury." Staked BIO also earns BioXP, described as "a loyalty program designed to reward active members with early access to new tokens," which is what gates allocation in new launches.
After launch, Bio manages secondary liquidity: "BIO can be paired in liquidity pools with project tokens (e.g., VITA/BIO, HAIR/BIO), as well as with base assets (e.g., BIO/ETH)." The protocol "receives 30% of a 1% fee applied to every secondary market trade of a launched project's token." Ongoing incentives are tied to science rather than price alone: "projects can unlock additional bio/acc rewards in the form of BIO tokens for hitting critical R&D milestones."
The documentation lists BIO's functions directly. Holders can "stake BIO to receive veBIO, which provides voting power on protocol upgrades," "commit BIO to invest in new projects during their initial fixed-price sale," and "use BIO to pay for services from ecosystem tools like BioAgents." BIO is also "the primary pair asset for all project tokens, creating deep liquidity pools," and holders "receive discounts on products and services offered by projects."
The design intent is that BIO sits underneath every BioDAO token rather than competing with them. Demand is meant to come from launch participation, liquidity pairing and governance rather than from a single application.
Bio applies token launch infrastructure to a domain where the underlying asset is intellectual property with a decade-long development horizon. Two features stand out. The first is IP tokenization, where governance over a research asset is fractionalized on-chain and BioDAOs can "act as a bridge to legacy institutions" by working with university tech transfer offices to bring patents on-chain. The second is milestone-linked rewards, where additional BIO is unlocked for hitting research milestones rather than for trading volume, which is an unusual attempt to tie token incentives to scientific output.
Against general-purpose launchpads, Bio is domain-specific and curates for scientific merit, with a permissioned track alongside the open one. Against IP infrastructure chains that focus on registering and licensing intellectual property broadly, Bio is narrower and funding-first, aimed at getting research capitalized and then managing the resulting market. Against data marketplaces for research and AI, Bio's unit of value is a governance stake in an IP asset rather than access to a dataset. Against a single research DAO, Bio is the layer that many such DAOs sit on, which means its exposure is portfolio-wide rather than tied to one therapeutic program.
BIO is deployed as a standard token on Ethereum, Base, BNB Chain and Solana, so token-level security follows those networks. Bio's documentation maintains a security section pointing to audits and security resources for its contracts, though the material reviewed does not name the audit firms. The larger security question for this category is not cryptographic. It is legal: whether an on-chain IP Token actually attaches to enforceable rights in the underlying patent or license. Bio's documentation is candid about the limit here, stating that IPT holders have "no guaranteed returns" and that "it's up to the IP owner whether IPT holders get paid if IP gets commercialized."
Biotech research fails often, and most early-stage programs never reach commercialization, so the underlying assets carry very high base-rate risk on multi-year timelines. IP Tokens confer governance and information rights, not a contractual claim on revenue, which is a distinction easy to miss. Liquidity in BioDAO tokens is typically thin, and BIO's role as the pairing asset means it absorbs volatility from the whole portfolio. The DeSci sector has seen sharp attention cycles that can decouple token activity from research progress. Regulatory treatment of tokenized IP and community-funded drug development is unsettled in most jurisdictions. Bio's own documentation does not name core team members, and governance concentration through veBIO staking is worth monitoring. Finally, cross-chain deployments mean users must verify they hold the correct contract on the correct network.
Early-stage biotech funding is narrow, slow and dominated by a small number of gatekeepers, and a great deal of university research never leaves the tech transfer office. Bio Protocol is one of the more developed attempts to widen that funnel using on-chain coordination, with a working portfolio of research DAOs, a real IP tokenization framework inherited from Molecule, and incentives that at least attempt to reward scientific milestones rather than speculation. It is an experiment with an unusually long feedback loop, which is exactly why the structure deserves attention.
BIO trades on major centralized exchanges following its Binance Launchpool distribution and January 2025 listing, and on decentralized exchanges across the chains where it is deployed. The documentation points to Uniswap on Ethereum and Base and Raydium on Solana. Because BIO exists on four networks with different addresses, confirm the correct contract for your chain from the official documentation or a block explorer before trading on-chain.
BIO can be held in any wallet supporting the relevant chain: EVM wallets for the Ethereum, Base and BNB Chain versions, and Solana wallets for the SPL version. Hardware wallets are appropriate for long-term holdings. If you intend to stake for veBIO or accumulate BioXP, those positions are locked in protocol contracts and are not freely transferable while staked, so plan around that before committing. Holding on an exchange keeps tokens liquid but forfeits governance participation and launch access, since those require staking from a wallet you control.
Suivez le prix en direct de Bio Protocol, son graphique, sa capitalisation et son volume en temps réel. Pratiquez le mock trading et le demo trading de Bio Protocol sur CoinRithm avant d'utiliser de l'argent réel.
Utilisez un compte de paper trading crypto pour faire du demo trading de Bio Protocol avec des prix en temps réel, du feedback IA et des ligues de trading. Testez des stratégies, apprenez la gestion du risque et gagnez en confiance avant de trader Bio Protocol avec de l'argent réel.
Lire le guide complet du paper tradingLe prix actuel de Bio Protocol est 0,02371 € avec un changement de 1,07 % au cours des dernières 24 heures.
Le volume d’échange quotidien est 303 358 € représentant un changement de 64,94 % au cours des dernières 24 heures.
La capitalisation boursière de Bio Protocol est 50 861 649 €, classé #277 mondialement.
La valorisation totalement diluée (FDV) de Bio Protocol est 78 721 859 €, calculée en supposant une offre maximale de 3 320 000 000 BIO.
En circulation : 2 145 029 070. Total : 3 320 000 000. Maximum : 3 320 000 000.
Au cours des dernières 24 heures, Bio Protocol s’est échangé entre un minimum de 0,02295 € et un maximum de 0,0238 €.
BIO/USDTTether USDT0,02754 USDT
Bio Protocol has launched OpenLabs, a platform that combines AI-assisted research development, community funding, and on-chain governance as its ecosystem surpasses $33 million in capital raised. According to Bio Protocol, the platform was introduced on June 19 during DeSci.Berlin 2026,…
NanoVita and Claw Intelligence team up to bring AI-driven nanotech research and bio-alpha insights directly to investors and traders on BNB Chain.
Victoria, Seychelles, 28th January 2026, Chainwire
YZi Labs is investing in Renewal Bio's groundbreaking stem cell technology to solve the global organ transplant shortage through regenerative medicine.
The data revealed a new list of the most successful crypto assets based on social activity and price actions, indicating investor attention and user interest.
